Welcome to our dedicated page for Aditxt news (Ticker: ADTX), a resource for investors and traders seeking the latest updates and insights on Aditxt stock.
Aditxt Inc (ADTX) is a pioneering biotechnology company developing innovative solutions to reprogram immune responses, with applications in organ transplantation and autoimmune disorders. This dedicated news hub provides investors and researchers with timely updates on clinical advancements, regulatory milestones, and strategic partnerships.
Access authoritative reporting on ADTX's flagship programs including Adimune for transplant tolerance and AditxtScore diagnostic platforms. Track developments in Apoptotic DNA Immunotherapy (ADi) and other novel approaches to immune modulation. The curated news feed covers earnings reports, research collaborations, and product pipeline updates while adhering to financial disclosure standards.
Bookmark this page for consolidated access to press releases, clinical trial data disclosures, and expert analyses of ADTX's position in the competitive immunotherapy landscape. Stay informed about technological breakthroughs through verified updates from primary sources.
Aditxt, Inc. (Nasdaq: ADTX) announced a public offering of 3,333,333 shares of common stock and associated warrants at $6.00 per unit, aiming to raise approximately $20 million. The warrants, with an exercise price of $6.00, are exercisable immediately and expire in five years. Proceeds will fund general corporate expenses, including R&D and potential acquisitions, although no current commitments are in place. Closing of the offering is expected around September 20, 2022, pending customary conditions. H.C. Wainwright & Co. is the exclusive placement agent.
Aditxt, Inc. (Nasdaq: ADTX) announced a 1-for-50 reverse stock split effective September 13, 2022. The split aims to comply with Nasdaq's $1.00 per share minimum bid price requirement. Post-split, approximately 1,156,674 shares will be outstanding with the CUSIP number 007025505. The reverse split was approved by stockholders during a special meeting on September 7, 2022. Trading on a post-split basis will begin on September 14, 2022. Aditxt focuses on immune system monitoring and modulation technologies.
Aditxt, Inc. (NASDAQ: ADTX) announces positive results from a toxicology study for its immunotherapeutic drug ADI™-100, aimed at treating autoimmune diseases and organ transplantation rejection. The study demonstrated a robust safety profile with no premature deaths or adverse clinical signs. These findings will support an upcoming Investigational New Drug (IND) application. Aditxt's commitment to advancing innovative solutions in the biotech sector is emphasized by the encouraging results, positioning ADI™-100 for potential human trials.
On June 14, 2022, Premier Medical Laboratory Services (PMLS) announced the addition of AditxtScore™ to its testing services, aimed at providing insights into patients' immunity profiles against SARS-CoV-2. The test assesses multiple antibodies and their effectiveness, enabling individuals to make informed decisions on vaccinations and risk mitigation. PMLS, a CAP accredited lab with extensive COVID-19 testing experience, emphasizes the importance of monitoring immunity trends as new variants emerge. AditxtScore™ can also help employers optimize testing protocols and reduce workplace disruptions.
Aditxt, Inc. (NASDAQ: ADTX) has announced a multiyear partnership with GRS, an affiliate of Guthy-Renker, to enhance awareness of its AditxtScore™ Immune Monitoring Platform. This collaboration aims to produce and broadcast TV commercials to boost visibility among consumers and healthcare providers. The AditxtScore™ technology, which provides insights into immune status related to COVID-19, is now fully operational in Richmond, VA. Aditxt's partnership with GRS leverages extensive marketing experience to facilitate a national rollout of AditxtScore™.
Aditxt, Inc. (NASDAQ: ADTX) has entered into a revenue-sharing agreement with Cellvera, enhancing its revenue strategy starting in 2022. The agreement aims to secure a $14.5 million loan while allowing Aditxt to earn up to 10% of Cellvera's net sales, reaching a maximum of $30 million. This deal is a step toward Aditxt's potential acquisition of Cellvera, which specializes in developing antiviral therapies. Due diligence for the acquisition is ongoing, with no guarantee of completion.
Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company, announced that CEO & Co-Founder Amro Albanna will present at the 2022 Virtual Growth Conference, hosted by Maxim Group LLC and M-Vest from March 28th - 30th between 9:00 a.m. - 5:00 p.m. EDT. This conference will cover various sectors, including biotech and healthcare, featuring presentations, discussions, and Q&As with executives. Aditxt focuses on mapping and reprogramming the immune system, aiming to address organ rejection and autoimmune diseases.
Aditxt has officially submitted two Emergency Use Authorization (EUA) applications for its AditxtScore™ COVID-19 test to the FDA, meeting the January 14 deadline. This comprehensive blood test assesses the immune response to COVID-19 and its variants, including Omicron. Notably, the test evaluates levels of neutralizing antibodies to the virus and those targeting its spike and nucleocapsid proteins. AditxtScore™ continues to be available during the FDA review process, aiming to provide critical insights into COVID-19 immunity.
Aditxt, Inc. (NASDAQ: ADTX) is participating in Edison Group’s Global Healthcare Open House Event from January 25 to 27, 2022. The virtual event, hosted in collaboration with the London Stock Exchange and Taylor Wessing, will cover topics including pharmaceuticals, AI, and healthcare technology. Presentations will be available for streaming on Edison’s website. Interested participants can register for free. Additionally, Aditxt focuses on immune system health and offers technology for immune monitoring and reprogramming, including the AditxtScore™ for COVID-19.
Aditxt, Inc. (ADTX), a biotech focused on immune system health, announced an online townhall on January 18, 2022, from 2:00 to 3:00 PM ET. Led by CEO Amro Albanna, the meeting will cover business updates, revenue strategy, and acquisition plans, followed by a Q&A session. Investors can submit questions in advance via email. Aditxt develops technologies for immune monitoring and reprogramming aimed at improving health and addressing various immune-related issues.
